Skip to main content
رجوع
Watch Compare

SANGAMO THERAPEUTICS, INC

جودة البيانات: 100%
SGMO
Nasdaq Manufacturing Chemicals
KWD 0.27
▲ KWD 0.02 (6.67%)
القيمة السوقية: 112.56 M
السعر
KWD 0.27
القيمة السوقية
112.56 M
نطاق اليوم
KWD 0.25 — KWD 0.28
نطاق 52 أسبوعًا
KWD 0.21 — KWD 0.84
حجم التداول
4,929,807
فتح KWD 0.25
متوسط 50 يوم / 200 يوم
KWD 0.38
28.95% below
متوسط 50 يوم / 200 يوم
KWD 0.49
44.36% below

Quick Summary

النقاط الرئيسية

Revenue declined -22.69% annually over 5 years
Negative free cash flow of -97.31 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 8.88%
Capital efficient — spends only 0.26% of revenue on capex

النمو

Revenue Growth (5Y)
-22.69%
أقل من متوسط القطاع (9.35%)
Revenue (1Y)-31.57%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-951.30%
أقل من متوسط القطاع (-51.02%)
ROIC-216.65%
Net Margin-310.81%
Op. Margin-306.53%

الأمان

Debt / Equity
N/A
Current Ratio0.88
Interest CoverageN/A

التقييم

PE (TTM)
-0.92
أعلى من متوسط القطاع (-1.98)
P/B Ratio18.03
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (44 نظير)
المقياس السهم وسيط القطاع
P/E -0.9 -2.0
P/B 18.0 5.1
ROE % -951.3 -51.0
Net Margin % -310.8 -150.2
Rev Growth 5Y % -22.7 9.3
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -31.57% Revenue Growth (3Y) -52.63%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -22.69% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 39.55 M Net Income (TTM) -122.93 M
ROE -951.30% ROA -132.04%
Gross Margin N/A Operating Margin -306.53%
Net Margin -310.81% Free Cash Flow (TTM) -97.31 M
ROIC -216.65% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.88
Interest Coverage N/A Asset Turnover 0.42
Working Capital -6.05 M Tangible Book Value 6.24 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.92 Forward P/E N/A
P/B Ratio 18.03 P/S Ratio 2.85
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -86.45%
Market Cap 112.56 M Enterprise Value 82.94 M
Per Share
EPS (Diluted TTM) -0.44 Revenue / Share 0.10
FCF / Share -0.23 OCF / Share -0.23
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.26% FCF Conversion 79.16%
SBC-Adj. FCF -107.57 M Growth Momentum -8.88

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 39.55 M 57.80 M 176.23 M 111.30 M 110.70 M
Net Income -122.93 M -97.94 M -257.83 M -192.28 M -178.29 M
EPS (Diluted) -0.44 -0.49 -1.48 -1.25 -1.23
Gross Profit — — — — —
Operating Income -121.24 M -103.97 M -274.01 M -201.28 M -183.34 M
EBITDA — — — — —
R&D Expenses 112.67 M 111.52 M 234.06 M 249.90 M 230.82 M
SG&A Expenses — — — — —
D&A 3.96 M 5.11 M 15.07 M 12.11 M 9.44 M
Interest Expense — — — — —
Income Tax -568,000.0 -167,000.0 -5.07 M 429,000.0 306,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 59.75 M 101.64 M 165.32 M 562.51 M 721.92 M
Total Liabilities 74.01 M 78.87 M 82.43 M 267.55 M 346.58 M
Shareholders' Equity -14.27 M 22.77 M 82.89 M 294.96 M 375.34 M
Total Debt — — — — —
Cash & Equivalents 20.95 M 41.92 M 45.20 M 100.44 M 178.87 M
Current Assets 35.83 M 51.69 M 94.33 M 300.33 M 398.77 M
Current Liabilities 42.47 M 45.81 M 47.73 M 111.71 M 127.89 M